Brief: Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
15/03/2024 12:29
March 15 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS: NASDAQ PANEL GRANTED REQUEST FOR
EXTENSION
TO EVIDENCE COMPLIANCE WITH ALL APPLICABLE CRITERIA FOR
CONTINUED LISTING ON NASDAQ
* AVENUE THERAPEUTICS INC: NASDAQ GRANTED EXTENSION THROUGH
MAY
20, 2024
Source text for Eikon: ID:nGNX75hmDW
Further company coverage: ATXI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi